Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Mylan to Commercialize Atomo Dx HIV Self-Tests in Low-, Middle-Income Nations

Mylan to Commercialize Atomo Dx HIV Self-Tests in Low-, Middle-Income Nations

Sep 24, 2018
|
staff reporter

NEW YORK (360Dx) — Atomo Diagnostics has signed an agreement to commercialize its CE-marked HIV self-tests in low- and middle-income nations with Mylan Pharmaceuticals, the companies announced today.

Atomo's tests use the firm's AtomoRapid technology to detect the presence of HIV antibodies from a finger prick of blood and provides results within 15 minutes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Infectious Disease

  1. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  2. Ortho Clinical Diagnostics Launches IPO at $20 to $23 Per Share

  3. Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

    Premium

  4. Finnish Diagnostic Firm Actim Gets CE Mark for SARS-CoV-2 Antibody Test

  5. Hamilton Storage, Harvard Spinout Rhinostics Partner for High-Throughput Sample Processing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.